Working… Menu

Hepatic Resection for Metastatic Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02892305
Recruitment Status : Recruiting
First Posted : September 8, 2016
Last Update Posted : May 8, 2020
Information provided by (Responsible Party):
Duke University

Brief Summary:
The purpose of this study is to demonstrate the feasibility of an aggressive multimodal approach among patients with stage IV pancreatic cancer (PAC) with isolated, low-volume hepatic metastasis (LVHM). We will evaluate and describe the surgical and overall outcomes of an initial cohort of subjects who undergo pancreatectomy and hepatic resection/ablation for PAC with LVHM. The end of study results will be reviewed by the Hepatiobiliary Multidisciplinary Conference (HDMC) and Surgery Audit Committee (SAC) to determine the appropriateness of adding this treatment arm for patients with oligometastatic metastatic pancreatic cancer.

Condition or disease Intervention/treatment
Pancreatic Neoplasms Neoplasm Metastasis Liver Metastases Procedure: Hepatic Resection or Ablation with Pancreaticoduodenectomy

Detailed Description:

This is a small interventional pilot study that will be conducted as a single-site study at Duke University Health System (DUHS). All subjects with pancreatic cancer and low-volume liver metastases (< or = 3 lesions) who meet criteria for pancreatic and liver resection will be offered the opportunity to participate. Potential subjects will be referred by the Medical Oncology physicians at Duke if they feel like the patient would be suitable for this study. We anticipate enrolling 15 subjects to include 10 evaluable subjects in the analysis.

Any subject who consents to the study will proceed with primary resection, including pancreaticoduodenectomy or distal pancreatectomy, and liver resection/ablation of the metastases.

Screening will include a medical record review, standard of care CT scan/MRI, clinical evaluation including physical, vitals, height weight and routine blood tests.

Preoperative data such as sex, race, age at resection, ASA class, race, body mass index (BMI), pretreatment staging, CA 19-9 (missing in open PD), tumor size (cm), and neoadjuvant therapy (no; yes), time to initiation and completion will also be captured.

Perioperative data like date of surgery, OR time, ASA class, intra-operative transfusion requirements, fluid administration, EBL, operative complications (including but not limited to infection, bleeding, need for re-operation, thrombus, pancreatic leak, bile leak, liver failure, nutritional data like use of TPN and tube feedings, and length of stay will be collected.

Post-operative data regarding re-admission and surveillance data for oncologic outcomes such as re-operation, final pathology margin status, nodal status, and postoperative CA 19-9, as well as DFS and OS, including date of death if applicable, during the provided follow up period.

To ensure accurate and complete incorporation of medical data, a database of perioperative outcomes will be prospectively maintained during the subject's hospital stay and for the first 3 months following surgery. Duke University is a member of the National Surgical Quality Improvement Program (NSQIP), with 100% participation in Hepatopancreaticobiliary (HPB) procedures. As such, all preoperative data and 30-day outcomes are collected by a fully trained Surgical Clinical Reviewer and are available within our electronic medical record (EMR). NSQIP provides a robust, audited dataset that has been validated to optimize the accuracy of data collection, substantially reducing the cost and resource requirements of data extraction. Following this 30-day period, data will be collected at regularly scheduled clinic visits, which typically occur weekly until 6-12 weeks post-surgery, then 3-4 months for the first year, and every 6 months thereafter and stored in a local, REDCap database.

Subjects' medical records will be continually reviewed for surgical complications and for overall survival (date of subject death).

Layout table for study information
Study Type : Observational
Estimated Enrollment : 15 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Hepatic Resection for Metastatic Pancreatic Cancer
Actual Study Start Date : May 18, 2018
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : August 2023

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Patients with pancreatic cancer and low-volume liver metastasis
Procedure: Hepatic Resection or Ablation with Pancreaticoduodenectomy

Patients will undergo pancreaticoduodenectomy, or the Whipple procedure, which involves removal of the head of the pancreas, the duodenum, and a portion of the stomach, as well as the gallbladder and a portion of the bile duct.

The patient will also undergo a Hepatectomy, the surgical resection or removal of all or part of the liver or Microwave Ablation (MWA) if determined by the surgeon to be the best course of care.

Other Names:
  • Whipple
  • Hepatectomy
  • Microwave Ablation

Primary Outcome Measures :
  1. 90-day mortality [ Time Frame: 90 days postoperatively ]
    Number of deaths within 90 days of operation

  2. Disease Progression [ Time Frame: up to 1 year postoperatively ]
    Time to disease progression

  3. Overall Survival [ Time Frame: up to 1 year postoperatively ]
    Number of months until death

Secondary Outcome Measures :
  1. Postoperative length of stay [ Time Frame: 90 days postoperatively ]
    Number of days in the hospital post-surgery

  2. Frequency of pancreatic leak [ Time Frame: 1-2 weeks postoperatively ]
    Number of leaks (Types A, B, C and bile)

  3. Readmission to hospital [ Time Frame: 90 days postoperatively ]
    Number of patients readmitted to the hospital post-operatively

  4. Margin status [ Time Frame: 90 days postoperatively ]
    Number of patients with positive margins

  5. Lymph node status [ Time Frame: 90 days postoperatively ]
    Number of positive lymph nodes

  6. Time to Adjuvant therapy [ Time Frame: Up to 5 years postoperatively ]
    Length of time to treatment after surgery

  7. OR time [ Time Frame: 1-2 days ]
    Length of time in the OR during surgery

  8. Intraoperative estimated blood loss [ Time Frame: 1-2 days ]
    Amount of blood loss during surgery in milliliters

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with biopsy-proven, or radiographically evident, resectable pancreatic head cancer who are found to have low-volume hepatic metastases at time of pancreaticoduodenectomy.

Inclusion Criteria:

  • Subject must be at least 18 years of age and at least the minimum Age of Majority according to applicable State or Country Law
  • Subject is a surgical candidate, (i.e., is able to undergo general anesthesia and surgical resection for diagnosis of cancer)
  • The Hepatobiliary Multidisciplinary Committee (HDMC) must approved of this intervention.
  • Insurance pre-authorization must be received unless the subject decides to pay out of pocket..
  • Subject has been informed of the study procedures and the treatment and has signed an informed consent form
  • less than or equal to 3 liver lesions

Exclusion Criteria:

  • Subject is not a suitable candidate for surgical intervention
  • The Hepatobiliary Multidisciplinary Committee (HDMC) disapproves of this intervention.
  • Insurance will not cover the procedure or subject not willing to pay out of pocket.
  • Pregnant women
  • Non-English speaking Subjects

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02892305

Layout table for location contacts
Contact: Felecia Walton 919-684-4235
Contact: Clancy Leahy, PhD, RN 919-681-0907

Layout table for location information
United States, North Carolina
Duke University Health System Recruiting
Durham, North Carolina, United States, 27710
Contact: Sabino Zani, MD    919-684-6553   
Sponsors and Collaborators
Duke University
Layout table for investigator information
Principal Investigator: Sabino Zani, MD Duke University Health System
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Duke University Identifier: NCT02892305    
Other Study ID Numbers: Pro00073208
First Posted: September 8, 2016    Key Record Dates
Last Update Posted: May 8, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Duke University:
Liver ablation
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Pancreatic Neoplasms
Neoplastic Processes
Pathologic Processes
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases